Prednisone tapering in RA
Presenter: Gerd-Rüdiger Burmester, Charité-Universitätsmedizin Berlin, Germany.
Wednesday 12 June: 16:15–17:45 (Abstract OP0030)
Rheumatoid arthritis patients who had stable low disease activity on tocilizumab plus conventional DMARDs and prednisone were randomly assigned to taper their prednisone dose or continue with the same dose in this 24-week study. The primary outcome is change in DAS28-ESR from baseline to week 24.
- News story | Glucocorticoid tapering recommended for RA patients responding to tocilizumab
- External link | Conference abstract
- External link | ClinicalTrials.gov registration page
- In-depth article | Should treatment be tapered in patients with RA